Pacira BioSciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
PCRX$36.49+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net income (loss) | $5,397 | $(115,601) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Goodwill impairment | — | 163,243 |
| Indefinite-lived intangible asset impairment | 25,866 | — |
| Investment impairment | 11,000 | — |
| Deferred taxes | 10,221 | 17,113 |
| Depreciation of fixed assets and amortization of intangible assets | 69,681 | 57,542 |
| Amortization of debt issuance costs | 2,320 | 2,284 |
| Amortization of debt discount | 101 | 70 |
| Loss (gain) on early extinguishment of debt | 983 | (7,518) |
| Stock-based compensation | 44,003 | 38,905 |
| Changes in contingent consideration | (2,407) | (5,541) |
| Other net gains | (5,887) | (53) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (1,943) | 4,903 |
| Inventories, net | (32,384) | (7,512) |
| Prepaid expenses and other assets | (13,911) | (6,338) |
| Accounts payable | (2,669) | 3,409 |
| Accrued expenses and income taxes payable | (7,145) | 12,546 |
| Other liabilities | 5,079 | (1,195) |
| Net cash provided by operating activities | 108,305 | 156,257 |
| Investing activities: | ||
| Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired) | (16,702) | — |
| Purchases of fixed assets | (15,115) | (8,518) |
| Purchases of available-for-sale investments | (113,450) | (207,017) |
| Sales of available-for-sale investments | 226,665 | 132,627 |
| Purchases of debt investments | (1,250) | — |
| Net cash provided by (used in) investing activities | 80,148 | (82,908) |
| Financing activities: | ||
| Proceeds from exercises of stock options | 12 | — |
| Proceeds from shares issued under employee stock purchase plan | 1,569 | 1,364 |
| Payment of employee withholding taxes on restricted stock unit vests | (5,474) | (414) |
| Purchase of treasury stock, inclusive of broker fees | (100,080) | (25,000) |
| Proceeds from 2029 convertible senior notes | — | 287,500 |
| Proceeds from Revolving Credit Facility | 101,000 | — |
| Repayment of 2024 convertible senior notes | — | (8,641) |
| Repayment of 2025 convertible senior notes | (202,487) | (190,994) |
| Repayment of Term loan A facility | (105,312) | (8,438) |
| Repayment of Revolving Credit Facility | (5,000) | — |
| Purchase of capped call transactions | — | (26,709) |
| Payment of debt issuance and financing costs | (2,203) | (9,350) |
| Net cash (used in) provided by financing activities | (317,975) | 19,318 |
| Effect of exchange rate changes on cash and cash equivalents | 337 | — |
| Net (decrease) increase in cash and cash equivalents | (129,185) | 92,667 |
| Cash and cash equivalents, beginning of period | 276,774 | 153,298 |
| Cash and cash equivalents, end of period | $147,589 | $245,965 |
| See accompanying condensed notes to consolidated financial statements. | ||
| PACIRA BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (In thousands)(Unaudited) | ||
|---|---|---|
| Nine Months EndedSeptember 30, | ||
| 2025 | 2024 | |
| Supplemental cash flow information: | ||
| Cash paid for interest | $10,390 | $10,191 |
| Net cash paid for income taxes | $8,944 | $9,575 |
| Non-cash investing and financing activities: | ||
| Fixed assets included in accounts payable and accrued liabilities | $1,116 | $415 |
| Excise tax on share repurchases included in accrued liabilities | $341 | $121 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.